Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia

Sohag University

Status: Not yet enrolling

Conditions: Androgenic Alopecia

Treatments: Procedure: autologous stromal vascular fraction

Study type: Interventional

Funder types: Other

Identifiers

NCT06326359

Soh-Med-24-02-03MD

Details and patient eligibility

About

Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia

Full description

40 Patients with androgenic alopecia will be randomly divided into 2 groups Group A (20): will receive 2 session of stromal vascular fraction directly after fat harvesting and processing and stromal vascular fraction extraction with 1 month interval .

Group B(20): will be injected with 2 session of Platelet rich plasma 3weeks interval at site of fat harvesting and will be followed 1 month later with fat aspiration from site where Platelet rich plasma was previously injected and this fat will undergo fat processing and stromal vascular fraction extraction followed by 2 session of stromal vascular fraction injection at scalp 1month interval .

Patients at both groups will receive topical and systemic antibiotics after stromal vascular fraction injection .

Enrollment: 40 estimated patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male patients with androgenic alopecia

Exclusion criteria

• Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.

Any other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area.

Any systemic disease as autoimmune disorders , cardiac hepatic and renal patients.

patients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

autologous stromal vascular fraction derived from denovo

Active Comparator group

Description:

autologous stromal vascular fraction derived from denovo in male androgenic alopecia

Treatment:

Procedure: autologous stromal vascular fraction

autologous stromal vascular fraction after platelet rich plasma enhanced donner site

Active Comparator group

Description:

autologous stromal vascular fraction after platelet rich plasma enhanced donner site in male androgenic alopecia

Treatment:

Procedure: autologous stromal vascular fraction